How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,532 results for

"cerebral palsy"

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Cerebral palsy in adults

Cerebral palsy in adults Cerebr Cerebral palsy in adults al palsy in adults NICE guideline Published: 15 January 2019 nice.org.uk/guidance/ng119 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cerebral palsy in adults (NG119) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 64Contents Contents Overview 5 Who is it for? 5 Recommendations 6 1.1 Service organisation 6 1.2 Function and participation 10 1.3

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Comprehensive care of the ambulatory child with cerebral palsy (GMFCS I and II): A Canadian perspective

Comprehensive care of the ambulatory child with cerebral palsy (GMFCS I and II): A Canadian perspective In Canada, cerebral palsy (CP) is the most common physical disability, affecting approximately 2 to 3 per 1000 individuals. Paediatricians are sure to encounter and care for children with CP and their families. The role of the general paediatrician in caring for a child with CP is crucial, from diagnosis to providing a ‘medical home’; from ensuring care coordination to delivering (...) levels I and II) on specific health issues and domains. Keywords:  Anticipatory guidance; Cerebral palsy; Wellness

2020 Canadian Paediatric Society

3. Single Event Multi-Level Surgeries for Children, Adolescents, and Young Adults with Cerebral Palsy or Other Similar Neuromotor Conditions

, Definitions for terms marked with *, and How to Cite this Guideline may be found in the Appendices. INTRODUCTION / BACKGROUND Cerebral Palsy (CP) is a disorder of movement and posture caused by a static, non-progressive, neurological incident, occurring in the fetal or infant brain. As a result, individuals often have secondary impairments including musculoskeletal pathologies consisting of abnormal muscle tone, loss of selective motor control, impaired balance, impaired posture, and impaired mobility (...) . slipped capital femoral epiphysis, avascular necrosis of the hip, lower extremity fractures, total hip replacements, selective dorsal rhizotomy) • Diagnoses other than CP or other like neuromotor conditions Evidence-Based Clinical Care Guideline for Physical Therapy Management of Single Event Multi-Level Surgeries for Children, Adolescents, and Young Adults with Cerebral Palsy or Other Similar Neuromotor Conditions Guideline (48) Copyright © 2018 Cincinnati Children's Hospital Medical Center; all

2019 Cincinnati Children's Hospital Medical Center

4. Cerebral palsy in under 25s: assessment and management

Cerebral palsy in under 25s: assessment and management Cerebr Cerebral palsy in under 25s: assessment al palsy in under 25s: assessment and management and management NICE guideline Published: 25 January 2017 nice.org.uk/guidance/ng62 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful (...) in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cerebral palsy in under 25s: assessment and management (NG62) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 46Contents

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

5. Cerebral palsy: When should I suspect cerebral palsy?

Cerebral palsy: When should I suspect cerebral palsy? When should I suspect cerebral palsy? | Diagnosis | Cerebral palsy | CKS | NICE Search CKS… Menu When should I suspect cerebral palsy? Cerebral palsy: When should I suspect cerebral palsy? June 2019 When should I suspect cerebral palsy? Children at increased of cerebral palsy (CP) should receive an enhanced clinical and developmental follow‑up programme by a multidisciplinary team up to the age of 2 years (corrected for gestational age (...) ). In practice, most people with cerebral palsy seen in primary care will therefore have already received a specialist diagnosis. Occasionally, CP may be suspected in a child presenting in primary care. Be aware that: Possible early motor features suggestive of CP include: Unusual fidgety movements or other abnormalities of movement, including asymmetry or paucity of movement. Abnormalities of tone, including hypotonia (floppiness), spasticity (stiffness) or dystonia (fluctuating tone). Abnormal motor

2016 NICE Clinical Knowledge Summaries

6. Cerebral palsy: Scenario: Suspected cerebral palsy

Cerebral palsy: Scenario: Suspected cerebral palsy Scenario: Suspected cerebral palsy | Management | Cerebral palsy | CKS | NICE Search CKS… Menu Scenario: Suspected cerebral palsy Cerebral palsy: Scenario: Suspected cerebral palsy June 2019 Scenario: Suspected cerebral palsy From age 1 month onwards. How should I manage a child with suspected cerebral palsy? Refer any child with suggestive of neurological disorders other than cerebral palsy (CP) to a specialist in paediatric neurology (...) , gastro-oesophageal reflux, or pain, use clinical judgement to manage appropriately. For more information, see the CKS topics on , , , and . Depending on the level of clinical suspicion, consider providing information on CP to the parents/carers. Patient information leaflets are available from the , , and . Basis for recommendation The recommendations on management of a child with suspected cerebral palsy are largely based on the National Institute of Health and Care Excellence (NICE) guideline

2016 NICE Clinical Knowledge Summaries

7. Cerebral palsy: Scenario: Child with confirmed cerebral palsy

Cerebral palsy: Scenario: Child with confirmed cerebral palsy Scenario: Child with confirmed cerebral palsy | Management | Cerebral palsy | CKS | NICE Search CKS… Menu Scenario: Child with confirmed cerebral palsy Cerebral palsy: Scenario: Child with confirmed cerebral palsy June 2019 Scenario: Child with confirmed cerebral palsy From age 1 month to 16 years. How should I manage a child with confirmed cerebral palsy? Children with CP should receive specialist management via a local integrated (...) hydrobromide, or with input from specialist services, trihexyphenidyl hydrochloride for children with dyskinetic cerebral palsy. GPs may subsequently be involved in prescribing these medications under local shared care arrangements. Other specialist interventions which may be offered to relieve drooling include high-dose botulinum toxin A injection to the salivary glands and in some situations salivary gland surgery. Pain — condition-specific causes of pain in people with CP include musculoskeletal

2016 NICE Clinical Knowledge Summaries

8. Cerebral palsy: Scenario: Adult with confirmed cerebral palsy

Cerebral palsy: Scenario: Adult with confirmed cerebral palsy Scenario: Adult with confirmed cerebral palsy | Management | Cerebral palsy | CKS | NICE Search CKS… Menu Scenario: Adult with confirmed cerebral palsy Cerebral palsy: Scenario: Adult with confirmed cerebral palsy June 2019 Scenario: Adult with confirmed cerebral palsy From age 16 years onwards. How should I manage an adult with confirmed cerebral palsy Note: When managing an adult with cerebral palsy (CP), adapt communication (...) methods and information resources to take account of the needs and understanding of the person and their family or carers (if appropriate). Adults with cerebral palsy (CP) should ideally be able to access a network of specialist services that (depending on local availability) may include advocacy support, learning disability services, mental health services, orthopaedic surgery (and post-surgery rehabilitation), rehabilitation engineering services (centres that design, develop, and adapt technological

2016 NICE Clinical Knowledge Summaries

9. Cerebral palsy: Baclofen

Cerebral palsy: Baclofen Baclofen | Prescribing information | Cerebral palsy | CKS | NICE Search CKS… Menu Baclofen Cerebral palsy: Baclofen June 2019 Baclofen Contraindications and cautions Do not prescribe baclofen to people with: Rare hereditary conditions of porphyria, galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption. Active peptic ulceration. Prescribe baclofen with caution to people: With cerebrovascular disease. With Parkinson's disease

2018 NICE Clinical Knowledge Summaries

10. Cerebral palsy

Cerebral palsy Cerebral palsy | Topics A to Z | CKS | NICE Search CKS… Menu Cerebral palsy Cerebral palsy June 2019 Cerebral palsy is a neurological condition which affects movement and co-ordination, caused by a problem with the brain that occurs before, during or soon after birth. Diagnosis Management Prescribing information Background information Cerebral palsy: Summary Cerebral palsy (CP) is an umbrella term for a group of permanent movement and posture disorders that limit activity (...) . The undelying cause is an acquired pathology within the developing brain during the prenatal, neonatal, or early infant period. The impaired movement associated with CP results from centrally-mediated abnormal muscle tone which leads (most commonly) to spasticity. CP can also incorporate disorders of sensation, perception, cognition, communication, and behaviour. Effects may include musculoskeletal problems, neurogenic bladder, gastro-oesophageal reflux, excessive salivation, and feeding and swallowing

2018 NICE Clinical Knowledge Summaries

11. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update Full Text available with Trip Pro

Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update Informing evidence‐based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update - Ozel - 2016 - Developmental Medicine & Child Neurology - Wiley Online Library The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

2016 Pediatric Endocrine Society

12. Cerebral Palsy Integrated Pathway Scotland

Cerebral Palsy Integrated Pathway Scotland Cerebral Palsy Integrated Pathway Scotland (CPIPS) DVD | Association of Paediatric Chartered Physiotherapists Username or email address. Password Remember me Don't have an account yet? Search Breadcrumb Cerebral Palsy Integrated Pathway Scotland (CPIPS) DVD Children with cerebral palsy (CP) are at risk of developing musculoskeletal problems such as muscle contractures, displacement of the hip and scoliosis. Hip dislocation leads to pain, decreased (...) , standardised physical and radiological assessments. This, in turn, allows the early identification of hip displacement and timely intervention. Monitoring and preventing progressive hip displacement has been the main aim of established hip surveillance programmes in other countries. In Sweden and Australia the incidence of hip dislocation has significantly reduced by earlier intervention after the introduction of the surveillance programmes. Cerebral Palsy Integrated Pathway Scotland (CPIPS) has been

2016 Chartered Society of Physiotherapy

13. Preterm Labour, Antibiotics and Cerebral Palsy

Preterm Labour, Antibiotics and Cerebral Palsy Preterm Labour, Antibiotics, and Cerebral Palsy Scientific Impact Paper No. 33 February 2013Preterm Labour, Antibiotics, and Cerebral Palsy 1. Introduction The rate of preterm birth (pregnancy under 37 +0 weeks of gestation) is 5–9% of all births in Europe, and 12–13% in the United States of America (USA); the rates in both continents increased up to 2008, partly due to the higher number of multiple births associated with assisted conceptions. 1 (...) , emotional and stressful times of their lives, 3 regardless of the longer term outcome. The sequelae of preterm birth also pose significant challenges. Children born preterm are at increased risk of major disabilities such as cerebral palsy. The risk of cerebal palsy increases as gestation at birth decreases. 4 Many children who were born preterm without disability develop significant behavioural and educational difficulties. 5 This paper will examine the evidence for: ? Prescribing antibiotics

2013 Royal College of Obstetricians and Gynaecologists

14. Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth

Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth Scientific Impact Paper No. 29 August 2011Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth 1. Background The prevalence of preterm birth is increasing. 1 While the survival of infants born preterm has improved, 2 the prevalence of cerebral palsy has risen. 3 The incidence of cerebral palsy decreases significantly with increasing (...) gestational age: 14.6% at 22–27 weeks of gestation, 6.2% at 28–31 weeks, 0.7% at 32–36 weeks and 0.1% in term infants. 4 Twenty-five percent of all cases of cerebral palsy are in infants born at less than 34 weeks of gestation. 5 In children born preterm the proportion whose cerebral palsy is considered to havea perinatal origin (49%) is greater than in those born at term (35%). 6,7 Strategies to reduce cerebral palsy in these infants should be considered and implemented if shown to be effective in order

2011 Royal College of Obstetricians and Gynaecologists

15. Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy

spasticity that warrants treatment, diazepam should be considered for short-term treatment, with caution regarding toxicity (Level B), and tizanidine may be considered (Level C). There are insufficient data to support or refute use of dantrolene, oral baclofen, or continuous intrathecal baclofen (Level U). Glossary AAN = American Academy of Neurology ; AE = adverse event ; AS = Ashworth scale ; BoNT-A = botulinum toxin type A ; BoNT-B = botulinum toxin type B ; CP = cerebral palsy ; FDA = Food and Drug (...) Administration ; GAS = Goal Attainment Scale ; GMFM = Gross Motor Function Measure ; ITB = intrathecal baclofen ; MAS = Modified Ashworth scale ; OT = occupational therapy ; PT = physiotherapy ; QUEST = Quality of Upper Extremity Skills Test ; TS = Tardieu scale. The prevalence of cerebral palsy (CP) was recently reported to be 3.6 cases per 1,000 in 8-year-old children, with very little variation among Western nations. More than 10,000 babies born in the United States each year will be affected by CP. CP

2010 American Academy of Neurology

18. Specialist neonatal respiratory care for babies born preterm

' postmenstrual age postmenstrual age Babies who receive dexamethasone are less likely to develop BPD compared with babies who do not receive dexamethasone. On average: without dexamethasone treatment, 63 babies per 100 would develop BPD (and 37 would not) with dexamethasone treatment, 47 babies per 100 would develop BPD (and 53 would not). There was evidence demonstrating this difference. Cerebr Cerebral palsy al palsy There is no difference in the incidence of cerebral palsy in babies who receive (...) dexamethasone compared with babies who do not receive dexamethasone. Although there was evidence demonstrating this lack of difference, there is uncertainty about the risk, so the possibility of cerebral palsy occurring cannot be excluded. Other Other neurode neurodev velopmental elopmental outcomes outcomes (neurode (neurodev velopmental elopmental dela delay and y and neurosensory neurosensory impairment) impairment) There is no difference in neurodevelopmental outcomes in babies who receive dexamethasone

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

19. Cannabis-based medicinal products

to treatment. Because there is limited evidence from trials on how reductions in spasticity affect quality of life and no evidence was found for conditions such as cerebral palsy, the committee agreed to make a Cannabis-based medicinal products (NG144) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 18 of 27research recommendation to inform future guidance. How the recommendations might affect pr How the recommendations

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

20. Prevention, Screening, Diagnosis, and Pregnancy Management for Fetal Neural Tube Defects

of a 22q11 deletion in a second-trimester fetus with conotruncal anomaly, absent thymus and meningomyelocele: Kousseff syndrome. J Obstet Gynaecol Res. 2012; 38 ( Available from: ) : 737-740 Chen CP Chromosomal abnormalities associated with neural tube defects (I): full aneuploidy. Taiwan J Obstet Gynecol. 2007; 46 ( Available from: ) : 325-335 Chen CP Chromosomal abnormalities associated with neural tube defects (II): partial aneuploidy. Taiwan J Obstet Gynecol. 2007; 46 ( Available from: ) : 336-351 (...) Chen CP Chen CY Chern SR Wu PS Chen SW Lai ST et al. Molecular cytogenetic characterization of a duplication of 15q24.2-q26.2 associated with anencephaly and neural tube defect. Taiwan J Obstet Gynecol. 2017; 56 ( Available from: ) : 550-553 Chen CP Chen YJ Chern SR Tsai FJ Lin HH Lee CC et al. Prenatal diagnosis of mosaic 1q31.3q32.1 trisomy associated with occipital encephalocele. Prenat Diagn. 2008; 28 : 865-867 Ekin A Gezer C Taner CE Ozeren M Ozer O Koc A et al. Chromosomal and structural

2021 Society of Obstetricians and Gynaecologists of Canada

Guidelines

Guidelines – filter by country